Meeting
2020 Gastrointestinal Cancers Symposium
Survival benefit of conversion therapy after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matched analysis.
Authors
Hiroyuki Ohnuma
Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan
Hiroyuki Ohnuma , Yasushi Sato , Ginji Omori , Naoki Onoyama , Saki Ameda , Ryo Ito , Kota Hamaguchi , Naotaka Hayasaka , Masanori Sato , Kazuyuki Murase , Kohichi Takada , Koji Miyanishi , Tatsuya Ito , Takayuki Nobuoka , Ichiro Takemasa , Junji Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 354)
Abstract #
354
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
First Author: Thomas Adam Abrams
Poster
2014 Gastrointestinal Cancers Symposium
Trastuzumab (T-mab) in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: Feasibility and preliminary efficacy.
First Author: Yasushi Sato
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni